Investigation of carbachol and PACAP38 in a human model of migraine

Danish Medical Bulletin

Volumn 57, Issue 12, 2010, Pages

  Schytz, Henrik Winther ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CARBACHOL; CHOLINERGIC RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; ANALGESIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; EXPERIMENTAL MODEL; HUMAN; MAST CELL DEGRANULATION; MIGRAINE; MIGRAINE WITHOUT AURA; NEUROGENIC INFLAMMATION; PAIN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; ADOLESCENT; BRAIN CIRCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANALGESICS, NON-NARCOTIC; CARBACHOL; CEREBROVASCULAR CIRCULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 78650217363     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (226)

1. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005 Jun;12 Suppl 1:1-27.
2. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population--a prevalence study. J Clin Epidemiol 1991;44(11):1147-1157.
3. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol 2005 Jun;12 Suppl 1:59-62.
4. WHO. The world health report 2001-mental health:new understanding, new hope (revised edn). Geneva: World Health Organization; 2002. p. 19-45.
5. Boni LJ, Ploug KB, Olesen J, Jansen-Olesen I, Gupta S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 2009 Feb 12.
6. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996 Dec 12;384(6609):560-564.
7. Offenhauser N, Zinck T, Hoffmann J, Schiemann K, Schuh-Hofer S, Rohde W, et al. CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 2005 Mar;25(3):225-236.
8. Eikermann-Haerter K, Moskowitz MA. Animal models of migraine headache and aura. Curr Opin Neurol 2008 Jun;21(3):294-300.
9. IHS. The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 2004;24(suppl.1):9-160.
10. Iversen HK. Human migraine models. Cephalalgia 2001 Sep;21(7):781-785.
11. Thomsen LL KC, Iversen HK, Olesen J. A nitric oxide donor triggers genuine migraine attacks. Eur J Neurol 1994;1:73-80.
12. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 1995 Jul 31;6(11):1475-1479.
13. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002 Feb;22(1):54-61.
14. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008 Apr 15;70(16):1304-1312.
15. Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998 Jan;18(1):27-32.
16. Obermann M, Yoon MS, Dommes P, Kuznetsova J, Maschke M, Weimar C, et al. Prevalence of trigeminal autonomic symptoms in migraine: a population-based study. Cephalalgia 2007 Jun;27(6):504-509.
17. Gupta R, Bhatia MS. A report of cranial autonomic symptoms in migraineurs. Cephalalgia 2007 Jan;27(1):22-28.
18. Spencer SE, Sawyer WB, Wada H, Platt KB, Loewy AD. CNS projections to the pterygopalatine parasympathetic preganglionic neurons in the rat: a retrograde transneuronal viral cell body labeling study. Brain Res 1990 Nov 26;534(1-2):149-1469.
19. Leblanc GG, Landis SC. Target specificity of neuropeptide Yimmunoreactive cranial parasympathetic neurons. J Neurosci 1988 Jan;8(1):146-155.
20. Uddman R, Malm L, Sundler F. The origin of vasoactive intestinal polypeptide (VIP) nerves in the feline nasal mucosa. Acta Otolaryngol 1980 Jan-Feb;89(1-2):152-156.
21. Hara H, Jansen I, Ekman R, Hamel E, MacKenzie ET, Uddman R, et al. Acetylcholine and vasoactive intestinal peptide in cerebral blood vessels: effect of extirpation of the sphenopalatine ganglion. J Cereb Blood Flow Metab 1989 Apr;9(2):204-211.
22. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med 2002 Jan 24;346(4):257-270.
23. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009 Jul;8(7):679-690.
24. Burstein R, Jakubowski M. Unitary hypothesis for multiple triggers of the pain and strain of migraine. J Comp Neurol 2005 Dec 5;493(1):9-14.
25. Gottselig R, Messlinger K. Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigeminoparasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache. Cephalalgia 2004 Mar;24(3):206-214.
26. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002 Feb;8(2):136-142.
27. Delepine L, Aubineau P. Plasma protein extravasation induced in the rat dura mater by stimulation of the parasympathetic sphenopalatine ganglion. Exp Neurol 1997 Oct;147(2):389-400.
28. Yarnitsky D, Goor-Aryeh I, Bajwa ZH, Ransil BI, Cutrer FM, Sottile A, et al. 2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache 2003 Jul- Aug;43(7):704-714.
29. Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA 1996 Jul 24-31;276(4):319-321.
30. Reutens DC, Fatovich DM, Stewart-Wynne EG, Prentice DA. Is intravenous lidocaine clinically effective in acute migraine? Cephalalgia 1991 Dec;11(6):245-247.
31. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. Brain Res 1999 Dec 4;849(1-2):1-15.
32. Edvinsson L, Uddman R. Adrenergic, cholinergic and peptidergic nerve fibres in dura mater--involvement in headache? Cephalalgia 1981 Dec;1(4):175-179.
33. Karczmar AG. Brief presentation of the story and present status of studies of the vertebrate cholinergic system. Neuropsychopharmacology 1993 Nov;9(3):181-199.
34. Edvinsson L, Nielsen KC, Owman C, Sporrong B. Cholinergic mechanisms in pial vessels. Histochemistry, electron microscopy and pharmacology. Z Zellforsch Mikrosk Anat 1972;134(3):311-325.
35. Edvinsson L, Owman C, Sjoberg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res 1976 Oct 22;115(3):377-393.
36. Edvinsson L, Gulbenkian S, Barroso CP, Cunha e Sa M, Polak JM, Mortensen A, et al. Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 1998;19(7):1213-1225.
37. Artico M, Cavallotti C. Catecholaminergic and acetylcholine esterase containing nerves of cranial and spinal dura mater in humans and rodents. Microsc Res Tech 2001 May 1;53(3):212-220.
38. Olesen IJ, Gulbenkian S, Valenca A, Antunes JL, Wharton J, Polak JM, et al. The peptidergic innervation of the human superficial temporal artery: immunohistochemistry, ultrastructure, and vasomotility. Peptides 1995;16(2):275-287.
39. Ferrari-DiLeo G, Potter LT. Alpha-adrenoreceptors and muscarine receptors in human pial arteries and microvessels: a receptor binding study. J Cereb Blood Flow Metab 1985 Sep;5(3):458-454.
40. Tsukahara T, Usui H, Taniguchi T, Shimohama S, Fujiwara M, Handa H. Characterization of muscarinic cholinergic receptors in human and dog cerebral arteries. Stroke 1986 Mar- Apr;17(2):300-305.
41. Benagiano V, Virgintino D, Rizzi A, Errede M, Bertossi M, Troccoli V, et al. Cholinergic nerve fibres associated with the microvessels of the human cerebral cortex: a study based on monoclonal immunocytochemistry for choline acetyltrasferase. Eur J Histochem 2000;44(2):165-169.
42. Walters BB, Gillespie SA, Moskowitz MA. Cerebrovascular projection from the sphenopalatine and otic ganglia to the middle cerebral artery of the cat. Stroke 1986 May-Jun;17(3):488-494.
43. Suzuki N, Hardebo JE, Owman C. Origins and pathways of choline acetyltransferase- positive parasympathetic nerve fibers to cerebral vessels in rat. J Cereb Blood Flow Metab 1990 May;10(3):399-408.
44. Parnavelas JG, Kelly W, Burnstock G. Ultrastructural localization of choline acetyltransferase in vascular endothelial cells in rat brain. Nature 1985 Aug 22-28;316(6030):724-725.
45. Arneric SP, Honig MA, Milner TA, Greco S, Iadecola C, Reis DJ. Neuronal and endothelial sites of acetylcholine synthesis and release associated with microvessels in rat cerebral cortex: ultrastructural and neurochemical studies. Brain Res 1988 Jun 28;454(1-2):11-30.
46. Gonzalez JL, Santo-Benito FF. Synthesis of acetylcholine by endothelial cells isolated from rat brain cortex capillaries. Brain Res 1987 May 26;412(1):148-150.
47. Ikeda C, Morita I, Mori A, Fujimoto K, Suzuki T, Kawashima K, et al. Phorbol ester stimulates acetylcholine synthesis in cultured endothelial cells isolated from porcine cerebral microvessels. Brain Res 1994 Aug 29;655(1-2):147-152.
48. Hamel E, Assumel-Lurdin C, Edvinsson L, Fage D, MacKenzie ET. Neuronal versus endothelial origin of vasoactive acetylcholine in pial vessels. Brain Res 1987 Sep 15;420(2):391-396.
49. Kasa P, Pakaski M, Joo F, Lajtha A. Endothelial cells from human fetal brain microvessels may be cholinoceptive, but do not synthesize acetylcholine. J Neurochem 1991 Jun;56(6):2143-2146.
50. Ferrari-Dileo G, Davis EB, Anderson DR. Biochemical evidence for cholinergic activity in retinal blood vessels. Invest Ophthalmol Vis Sci 1989 Mar;30(3):473-477.
51. Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988 Jul;1(5):403-410.
52. Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989 Apr;12(4):148-151.
53. Caulfield MP. Muscarinic receptors--characterization, coupling and function. Pharmacol Ther 1993 Jun;58(3):319-379.
54. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998 Jun;50(2):279-290.
55. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009 Jan;89(1):73-120.
56. Itier V, Bertrand D. Neuronal nicotinic receptors: from protein structure to function. FEBS Lett 2001 Aug 31;504(3):118-125.
57. Changeux JP, Edelstein SJ. Allosteric receptors after 30 years. Neuron 1998 Nov;21(5):959-980.
58. Faraci FM. Role of endothelium-derived relaxing factor in cerebral circulation: large arteries vs. microcirculation. Am J Physiol 1991 Oct;261(4 Pt 2):H1038-H1042.
59. Dauphin F, Hamel E. Identification of multiple muscarinic binding site subtypes in cat and human cerebral vasculature. J Pharmacol Exp Ther 1992 Feb;260(2):660-667.
60. Tsukahara T, Kassell NF, Hongo K, Vollmer DG, Ogawa H. Muscarinic cholinergic receptors on the endothelium of human cerebral arteries. J Cereb Blood Flow Metab 1989 Dec;9(6):748-753.
61. Elhusseiny A, Hamel E. Muscarinic--but not nicotinic--acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J Cereb Blood Flow Metab 2000 Feb;20(2):298-305.
62. Lee TJ. Cholinergic mechanism in the large cat cerebral artery. Circ Res 1982 Jun;50(6):870-879.
63. Dauphin F, Hamel E. Muscarinic receptor subtype mediating vasodilation feline middle cerebral artery exhibits M3 pharmacology. Eur J Pharmacol 1990 Mar 20;178(2):203-213.
64. Dauphin F, Linville DG, Hamel E. Cholinergic dilatation and constriction of feline cerebral blood vessels are mediated by stimulation of phosphoinositide metabolism via two different muscarinic receptor subtypes. J Neurochem 1994 Aug;63(2):544-551.
65. Toda N, Ayajiki K, Okamura T. Inhibition of nitroxidergic nerve function by neurogenic acetylcholine in monkey cerebral arteries. J Physiol 1997 Jan 15;498 (Pt 2):453-461.
66. Liu J, Lee TJ. Mechanism of prejunctional muscarinic receptor-mediated inhibition of neurogenic vasodilation in cerebral arteries. Am J Physiol 1999 Jan;276(1 Pt 2):H194-H204.
67. Zhang W, Edvinsson L, Lee TJ. Mechanism of nicotine-induced relaxation in the porcine basilar artery. J Pharmacol Exp Ther 1998 Feb;284(2):790-797.
68. Si ML, Lee TJ. Alpha7-nicotinic acetylcholine receptors on cerebral perivascular sympathetic nerves mediate choline-induced nitrergic neurogenic vasodilation. Circ Res 2002 Jul 12;91(1):62-69.
69. Tanelian DL. Cholinergic activation of a population of corneal afferent nerves. Exp Brain Res 1991;86(2):414-420.
70. Steen KH, Reeh PW. Actions of cholinergic agonists and antagonists on sensory nerve endings in rat skin, in vitro. J Neurophysiol 1993 Jul;70(1):397-405.
71. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 2003 May;89(5):2441-2448.
72. Dimitriadou V, Lambracht-Hall M, Reichler J, Theoharides TC. Histochemical and ultrastructural characteristics of rat brain perivascular mast cells stimulated with compound 48/80 and carbachol. Neuroscience 1990;39(1):209-224.
73. Blandina P, Fantozzi R, Mannaioni PF, Masini E. Characteristics of histamine release evoked by acetylcholine in isolated rat mast cells. J Physiol 1980 Apr;301:281-293.
74. Reynier-Rebuffel AM, Callebert J, Dimitriadou V, Mathiau P, Launay JM, Seylaz J, et al. Carbachol induces granular cell exocytosis and serotonin release in rabbit cerebral arteries. Am J Physiol 1992 Jan;262(1 Pt 2):R105-R111.
75. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed ed. New York: McGraw-Hill; 2001.
76. Carratala C, Gea JG, Aguar MC, Grau S, Espadaler-Medina JM, Broquetas JM. Methacholine induced headache. Thorax 1995 Mar;50(3):319.
77. Okada F, Miyagishi T, Honma M, Ui M. Plasma cyclic nucleotide responses to methacholine and epinephrine in patients with migraine. Headache 1984 Jan;24(1):26-29.
78. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000 Jun;52(2):269-324.
79. Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 1991 Nov;129(5):2787-2789.
80. Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM, Bloom SR. Distribution, molecular characterization of pituitary adenylate cyclaseactivating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol 1993 Jan;136(1):159-166.
81. Hannibal J, Mikkelsen JD, Clausen H, Holst JJ, Wulff BS, Fahrenkrug J. Gene expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat hypothalamus. Regul Pept 1995 Jan 26;55(2):133-148.
82. Mikkelsen JD, Hannibal J, Fahrenkrug J, Larsen PJ, Olcese J, McArdle C. Pituitary adenylate cyclase activating peptide-38 (PACAP-38), PACAP-27, and PACAP related peptide (PRP) in the rat median eminence and pituitary. J Neuroendocrinol 1995 Jan;7(1):47-55.
83. Fahrenkrug J. PACAP--a multifacetted neuropeptide. Chronobiol Int 2006;23(1-2):53-61.
84. Uddman R, Goadsby PJ, Jansen I, Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 1993 Mar;13(2):291-297.
85. Jansen-Olesen I, Goadsby PJ, Uddman R, Edvinsson L. Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. J Auton Nerv Syst 1994 Sep;49 Suppl:S97-S103.
86. Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ. Origin and Colocalization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 2001 May 1;53(3):221-228.
87. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999 May 28;76(2-3):176-183.
88. Uddman R, Tajti J, Moller S, Sundler F, Edvinsson L. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 1999 May 1;826(2):193-199.
89. Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002 Mar;22(2):112-116.
90. Mulder H, Uddman R, Moller K, Elsas T, Ekblad E, Alumets J, et al. Pituitary adenylate cyclase activating polypeptide is expressed in autonomic neurons. Regul Pept 1995 Sep 22;59(1):121-128.
91. Savage MV, Brengelmann GL, Buchan AM, Freund PR. Cystic fibrosis, vasoactive intestinal polypeptide, and active cutaneous vasodilation. J Appl Physiol 1990 Dec;69(6):2149-154.
92. Schulze E, Witt M, Fink T, Hofer A, Funk RH. Immunohistochemical detection of human skin nerve fibers. Acta Histochem 1997 Aug;99(3):301-309.
93. Groneberg DA, Welker P, Fischer TC, Dinh QT, Grutzkau A, Peiser C, et al. Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol 2003 May;111(5):1099-1105.
94. Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE. Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Pept 1999 Mar 17;80(1-2):49-55.
95. Odum L, Petersen LJ, Skov PS, Ebskov LB. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 1998 Dec;47(12):488-492.
96. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclaseactivating polypeptide. Pharmacol Rev 1998 Jun;50(2):265-270.
97. Dickson L, Finlayson K. VPAC and PAC receptors: From ligands to function. Pharmacol Ther 2009 Mar;121(3):294-316.
98. Dickinson T, Fleetwood-Walker SM. VIP and PACAP: very important in pain? Trends Pharmacol Sci 1999 Aug;20(8):324-329.
99. Knutsson M, Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 2002 Mar 25;13(4):507-509.
100. Seki Y, Suzuki Y, Baskaya MK, Kano T, Saito K, Takayasu M, et al. The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur J Pharmacol 1995 Mar 14;275(3):259-266.
101. Juhl Boni L, Beri Ploug K, Maddahi A, Edvinsson L, Olesen J, Jansen-Olesen I, et al. The in vivo effect of VIP, PACAP-38 and PACAP-27 and expression of their receptors in rat middle artery. In press 2008.
102. Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 2007 May 3;140(3):185-191.
103. Hashimoto H, Shintani N, Baba A. New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor- knockout mice. Ann N Y Acad Sci 2006 Jul;1070:75-89.
104. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 2006 Aug;26(8):992-1003.
105. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008 Mar;28(3):226-236.
106. IHS. The International Classification of Headache Disorders. Cephalalgia. 2nd ed 2004.
107. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989 Jul;38(1):17-24.
108. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006 Jun;26(6):742-746.
109. Busija DW, Heistad DD, Marcus ML. Continuous measurement of cerebral blood flow in anesthetized cats and dogs. Am J Physiol 1981 Aug;241(2):H228-H234.
110. Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K. Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT. Stroke 1989 Dec;20(12):1733-1736.
111. Thomsen LL, Iversen HK. Experimental and biological variation of threedimensional transcranial Doppler measurements. J Appl Physiol 1993 Dec;75(6):2805-2810.
112. Markwalder TM, Grolimund P, Seiler RW, Roth F, Aaslid R. Dependency of blood flow velocity in the middle cerebral artery on end-tidal carbon dioxide partial pressure--a transcranial ultrasound Doppler study. J Cereb Blood Flow Metab 1984 Sep;4(3):368-372.
113. Edvinsson L. MacKenzie ET. Fundamental responses of the cerebral circulation. Cerebral blood flow and metabolism. New York: Raven Press; 1993. p. 497-523.
114. Vorstrup S. Tomographic cerebral blood flow measurements in patients with ischemic cerebrovascular disease and evaluation of the vasodilatory capacity by the acetazolamide test. Acta Neurol Scand Suppl 1988;114:1-48.
115. Carroll TJ, Teneggi V, Jobin M, Squassante L, Treyer V, Hany TF, et al. Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography. J Cereb Blood Flow Metab 2002 Sep;22(9):1149-1156.
116. Celsis P, Goldman T, Henriksen L, Lassen NA. A method for calculating regional cerebral blood flow from emission computed tomography of inert gas concentrations. J Comput Assist Tomogr 1981 Oct;5(5):641-645.
117. Kruuse C, Jacobsen TB, Thomsen LL, Hasselbalch SG, Frandsen EK, Dige-Petersen H, et al. Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects. Eur J Neurol 2000 Nov;7(6):629-638.
118. Shirahata N, Henriksen L, Vorstrup S, Holm S, Lauritzen M, Paulson OB, et al. Regional cerebral blood flow assessed by 133Xe inhalation and emission tomography: normal values. J Comput Assist Tomogr 1985 Sep-Oct;9(5):861-866.
119. Nielsen TH, Iversen HK, Tfelt-Hansen P, Olesen J. Small arteries can be accurately studied in vivo, using high frequency ultrasound. Ultrasound Med Biol 1993;19(9):717-725.
120. Nielsen TH, Iversen HK, Tfelt-Hansen P. Determination of the luminal diameter of the radial artery in man by high frequency ultrasound: a methodological study. Ultrasound Med Biol 1990;16(8):787-791.
121. Olesen J, Tfelt-Hansen P, Ashina M. Finding new drug targets for the treatment of migraine attacks. Cephalalgia 2009 Feb 25.
122. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Bmj 1990 Jan 27;300(6719):230-235.
123. Fullerton A, Fischer T, Lahti A, Wilhelm KP, Takiwaki H, Serup J. Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1996 Jul;35(1):1-10.
124. Drewes AM, Helweg-Larsen S, Petersen P, Brennum J, Andreasen A, Poulsen LH, et al. McGill Pain Questionnaire translated into Danish: experimental and clinical findings. Clin J Pain 1993 Jun;9(2):80-87.
125. Van der Schueren BJ, de Hoon JN, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, et al. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. Br J Clin Pharmacol 2007 Nov;64(5):580-590.
126. Gazerani P, Andersen OK, Arendt-Nielsen L. A human experimental capsaicin model for trigeminal sensitization. Gender-specific differences. Pain 2005 Nov;118(1-2):155-163.
127. Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpaa M, Jorum E, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004 Mar;11(3):153-162.
128. Gazerani P, Andersen OK, Arendt-Nielsen L. Site-specific, dosedependent, and sex-related responses to the experimental pain model induced by intradermal injection of capsaicin to the foreheads and forearms of healthy humans. J Orofac Pain 2007 Fall;21(4):289-302.
129. Essex TJ, Byrne PO. A laser Doppler scanner for imaging blood flow in skin. J Biomed Eng 1991 May;13(3):189-194.
130. Magerl W, Szolcsanyi J, Westerman RA, Handwerker HO. Laser Doppler measurements of skin vasodilation elicited by percutaneous electrical stimulation of nociceptors in humans. Neurosci Lett 1987 Dec 4;82(3):349-354.
131. Forster C, Greiner T, Nischik M, Schmelz M, Handwerker HO. Neurogenic flare responses are heterogeneous in superficial and deep layers of human skin. Neurosci Lett 1995 Feb 6;185(1):33-66.
132. Serra J, Campero M, Ochoa J. Flare and hyperalgesia after intradermal capsaicin injection in human skin. J Neurophysiol 1998 Dec;80(6):2801-2810.
133. Quinn AG, McLelland J, Essex T, Farr PM. Measurement of cutaneous inflammatory reactions using a scanning laser-Doppler velocimeter. Br J Dermatol 1991 Jul;125(1):30-37.
134. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000 May;47(5):614-624.
135. Schytz HW, Wienecke T, Oturai PS, Olesen J, Ashina M. The cholinomimetic agent carbachol induces headache in healthy subjects. Cephalalgia 2009 Feb;29(2):258-268.
136. Schytz HW, Wienecke T, Olesen J, Ashina M. Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. Cephalalgia 2009 Jul 9.
137. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009 Jan;132(Pt 1):16-25.
138. Schytz HW, Holst H, Arendt-Nielsen L, Olesen L, Ashina M. Cutaneous nociception and neurogenic inflammation evoked by VIP and PACAP38: a human experimental study. Submitted for publication in PAIN 2009.
139. Hamilton CA, Williams R, Pathi V, Berg G, McArthur K, McPhaden AR, et al. Pharmacological characterisation of endothelium-dependent relaxation in human radial artery: comparison with internal thoracic artery. Cardiovasc Res 1999 Apr;42(1):214-223.
140. Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987 Jul 2;139(1):19-30.
141. Alm R, Edvinsson L, Malmsjo M. Organ culture: a new model for vascular endothelium dysfunction. BMC Cardiovasc Disord 2002 May 5;2:8.
142. Forstermann U, Hertting G, Neufang B. The role of endothelial and nonendothelial prostaglandins in the relaxation of isolated blood vessels of the rabbit induced by acetylcholine and bradykinin. Br J Pharmacol 1986 Mar;87(3):521-532.
143. Buus NH, Simonsen U, Pilegaard HK, Mulvany MJ. Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol 2000 Jan;129(1):184-192.
144. Jiang F, Li CG, Rand MJ. Mechanisms of nitric oxide-independent relaxations induced by carbachol and acetylcholine in rat isolated renal arteries. Br J Pharmacol 2000 Jul;130(6):1191-1200.
145. Thomsen LL. Investigations into the role of nitric oxide and the large intracranial arteries in migraine headache. Cephalalgia 1997 Dec;17(8):873-895.
146. Levy D, Strassman AM. Modulation of dural nociceptor mechanosensitivity by the nitric oxide-cyclic GMP signaling cascade. J Neurophysiol 2004 Aug;92(2):766-772.
147. Tassorelli C, Blandini F, Greco R, Nappi G. Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. J Chem Neuroanat 2004 Mar;27(1):23-32.
148. Koulchitsky S, Fischer MJ, De Col R, Schlechtweg PM, Messlinger K. Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat--possible implications for the pathophysiology of headaches. J Neurophysiol 2004 Sep;92(3):1320-1328.
149. Tvedskov JF, Thomsen LL, Iversen HK, Williams P, Gibson A, Jenkins K, et al. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia 2004 Dec;24(12):1076-1087.
150. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991 Jul 6;338(8758):13-17.
151. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet 1990 Oct 6;336(8719):837-839.
152. Gonzalez C, Martin C, Hamel E, Galea E, Gomez B, Lluch S, et al. Endothelial cells inhibit the vascular response to adrenergic nerve stimulation by a receptor-mediated mechanism. Can J Physiol Pharmacol 1990 Jan;68(1):104-109.
153. Levy D. Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep 2009 Jun;13(3):237-240.
154. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 2005 Jul;49(1):65-76.
155. Heatley RV, Denburg JA, Bayer N, Bienenstock J. Increased plasma histamine levels in migraine patients. Clin Allergy 1982 Mar;12(2):145-149.
156. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007 Jul;130(1-2):166-176.
157. Zhang XC, Strassman AM, Burstein R, Levy D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 2007 Aug;322(2):806-812.
158. Nanda RN, Arthur GP, Johnson RH, Lambie DG. Cimetidine in the prophylaxis of migraine. Acta Neurol Scand 1980 Aug;62(2):90-95.
159. Koch-Henriksen N, Sehested P. FPL 57787 and migraine prophylaxis. A double-blind cross-over study. Acta Neurol Scand 1979 Mar;59(2-3):154-155.
160. Fantozzi R, Masini E, Blandina P, Mannaioni PF, Bani-Sacchi T. Release of histamine from rat mast cells by acetylcholine. Nature 1978 Jun 8;273(5662):473-474.
161. Fantozzi R, Moroni F, Masini E, Blandina P, Mannaioni PF. Modulation of the spontaneous histamine release by adrenergic and cholinergic drugs. Agents Actions 1978 Jun;8(4):347-358.
162. Wilson A SH. The effect of the injection of acetylcholine into the brachial artery of normal subjects and patients with myasthenia gravis. Q J Med 1947;16:237-243.
163. Armstrong D, Dry RM, Keele CA, Markham JW. Observations on chemical excitants of cutaneous pain in man. J Physiol 1953 May 28;120(3):326-351.
164. Thuerauf N, Kaegler M, Dietz R, Barocka A, Kobal G. Dose-dependent stereoselective activation of the trigeminal sensory system by nicotine in man. Psychopharmacology (Berl) 1999 Mar;142(3):236-243.
165. Dussor GO, Leong AS, Gracia NB, Kilo S, Price TJ, Hargreaves KM, et al. Potentiation of evoked calcitonin gene-related peptide release from ora lmucosa: a potential basis for the pro-inflammatory effects of nicotine. Eur J Neurosci 2003 Nov;18(9):2515-2526.
166. Bernardini N, Sauer SK, Haberberger R, Fischer MJ, Reeh PW. Excitatory nicotinic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin. J Neurosci 2001 May 1;21(9):3295-3302.
167. Hu WP, Ma SY, Wu JL, Li ZW. 5-Hydroxytryptamine directly inhibits neuronal nicotinic acetylcholine receptors in rat trigeminal ganglion neurons. Eur J Pharmacol 2007 Nov 28;574(2-3):120-126.
168. Goadsby PJ. Migraine: diagnosis and management. Intern Med J 2003 Sep-Oct;33(9-10):436-442.
169. Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endotheliumderived relaxing factor in the cat. Neurosci Lett 1985 Jul 31;58(2):213-217.
170. Warren JB, Donnelly LE, Cullen S, Robertson BE, Ghatei MA, Bloom SR, et al. Pituitary adenylate cyclase-activating polypeptide: a novel, longlasting, endothelium-independent vasorelaxant. Eur J Pharmacol 1991 May 17;197(2-3):131-134.
171. Kastner A, Bruch L, Will-Shahab L, Modersohn D, Baumann G. Pituitary adenylate cyclase activating peptides are endothelium-independent dilators of human and porcine coronary arteries. Agents Actions Suppl 1995;45:283-289.
172. Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 2000 Aug;20(8):1205-1214.
173. Grant S, Lutz EM, McPhaden AR, Wadsworth RM. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries. J Cereb Blood Flow Metab 2006 Jan;26(1):58-67.
174. Cardell LO, Hjert O, Uddman R. The induction of nitric oxide-mediated relaxation of human isolated pulmonary arteries by PACAP. Br J Pharmacol 1997 Mar;120(6):1096-1100.
175. Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993 Nov;267(2):690-696.
176. Jansen-Olesen I, Gulbenkian S, Engel U, Cunha e Sa M, Edvinsson L. Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides 2004 Dec;25(12):2105-2114.
177. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008 Mar;123(3):398-410.
178. Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997 May;17(3):166-174.
179. Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 2004;10(12):1325-1340.
180. Dickson L, Aramori I, McCulloch J, Sharkey J, Finlayson K. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology 2006 Nov;51(6):1086-1098.
181. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989 Oct 16;164(1):567-574.
182. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headacheinducing effect of cilostazol in human volunteers. Cephalalgia 2006 Nov;26(11):1304-1309.
183. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005 Mar;77(3):202-213.
184. Levy D, Strassman AM. Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors. J Physiol 2002 Jan 15;538(Pt 2):483-493.
185. Ingram SL, Williams JT. Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol 1996 Apr 1;492 (Pt 1):97-106.
186. Margiotta JF, Pardi D. Pituitary adenylate cyclase-activating polypeptide type I receptors mediate cyclic AMP-dependent enhancement of neuronal acetylcholine sensitivity. Mol Pharmacol 1995 Jul;48(1):63-71.
187. Gurantz D, Harootunian AT, Tsien RY, Dionne VE, Margiotta JF. VIP modulates neuronal nicotinic acetylcholine receptor function by a cyclic AMP-dependent mechanism. J Neurosci 1994 Jun;14(6):3540-3547.
188. Zagami AS, Edvinsson L, L. HK, Goadsby PJ. Stimulation of the superior sagittal sinus causes extracranial release of PACAP. Cephalalgia 1995:Suppl. 14,109.
189. Tajti J, Uddman R, Edvinsson L. Neuropeptide localization in the migraine generator region of the human brainstem. Cephalalgia 2001 Mar;21(2):96-101.
190. Basbaum AI, Clanton CH, Fields HL. Three bulbospinal pathways from the rostral medulla of the cat: an autoradiographic study of pain modulating systems. J Comp Neurol 1978 Mar 15;178(2):209-224.
191. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995 Jul;1(7):658-660.
192. Zhang Y, Malmberg AB, Yaksh TL, Sjolund B, Sundler F, Hakanson R. Capsaicin- evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo. Regul Pept 1997 Mar 26;69(2):83-87.
193. Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T, et al. Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 2004 Aug 18;24(33):7283-7291.
194. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 2003 Dec;26(12):696-705.
195. Jongsma H, Pettersson LM, Zhang Y, Reimer MK, Kanje M, Waldenstrom A, et al. Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. Neuroreport 2001 Jul 20;12(10):2215-2219.
196. Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, et al. Central Pituitary Adenylate Cyclase 1 Receptors Modulate Nociceptive Behaviors in Both Inflammatory and Neuropathic Pain States. J Pain 2008 Mar 10.
197. Ohsawa M, Brailoiu GC, Shiraki M, Dun NJ, Paul K, Tseng LF. Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse. Pain 2002 Nov;100(1-2):27-34.
198. van Zwieten PA, Doods HN. Muscarinic receptors and drugs in cardiovascular medicine. Cardiovasc Drugs Ther 1995 Feb;9(1):159-167.
199. McCulloch AI, Bottrill FE, Randall MD, Hiley CR. Characterization and modulation of EDHF-mediated relaxations in the rat isolated superior mesenteric arterial bed. Br J Pharmacol 1997 Apr;120(8):1431-1438.
200. Schmidt R, Schmelz M, Weidner C, Handwerker HO, Torebjork HE. Innervation territories of mechano-insensitive C nociceptors in human skin. J Neurophysiol 2002 Oct;88(4):1859-1866.
201. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003 Jan;126(Pt 1):241-247.
202. Wienecke T, Olesen J, Ashina M. Prostaglandin I2 (Epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 2009;In Press.
203. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 2008 Sep 30;139(1):106-116.
204. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2(PGE2) induces headache in healthy subjects. Cephalalgia 2009 May;29(5):509-519.
205. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol 2008 Feb;63(2):148-158.
206. de Tommaso M, Losito L, Libro G, Guido M, Di Fruscolo O, Sardaro M, et al. Effects of symptomatic treatments on cutaneous hyperalgesia and laser evoked potentials during migraine attack. Cephalalgia 2005 May;25(5):359-368.
207. Schmelz M, Michael K, Weidner C, Schmidt R, Torebjork HE, Handwerker HO. Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport 2000 Feb 28;11(3):645-548.
208. Warren JB, Cockcroft JR, Larkin SW, Kajekar R, Macrae A, Ghatei MA, et al. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J Cardiovasc Pharmacol 1992 Jul;20(1):83-87.
209. Hovell CJ, Beasley CR, Mani R, Holgate ST. Laser Doppler flowmetry for determining changes in cutaneous blood flow following intradermal injection of histamine. Clin Allergy 1987 Sep;17(5):469-479.
210. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987 Dec;7(12):4129-4136.
211. Moskowitz MA, Reinhard JF, Jr., Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet 1979 Oct 27;2(8148):883-885.
212. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993 Jun;43(6 Suppl 3):S16-S20.
213. Jensen K, Tuxen C, Pedersen-Bjergaard U, Jansen I, Edvinsson L, Olesen J. Pain, wheal and flare in human forearm skin induced by bradykinin and 5-hydroxytryptamine. Peptides 1990 Nov-Dec;11(6):1133-1138.
214. Beasley R, Hovel C, Mani R, Robinson C, Varley J, Holgate ST. Comparative vascular effects of histamine, prostaglandin (PG) D2 and its metabolite 9 alpha,11 beta-PGF2 in human skin. Clin Allergy 1988 Nov;18(6):619-627.
215. Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ. Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 1986 Oct;87(4):533-536.
216. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Olesen J. Calcitonin gene-related peptide, neurokinin A and substance P: effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides 1991 Mar-Apr;12(2):333-337.
217. Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005 Nov;58(5):698-705.
218. Lischetzki G, Rukwied R, Handwerker HO, Schmelz M. Nociceptor activation and protein extravasation induced by inflammatory mediators in human skin. Eur J Pain 2001;5(1):49-57.
219. May A, Shepheard SL, Knorr M, Effert R, Wessing A, Hargreaves RJ, et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998 Jul;121 (Pt 7):1231-1237.
220. Roon KI, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH, et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo- controlled clinical trials. Ann Neurol 2000 Feb;47(2):238-241.
221. Polley JS, Gaskin PJ, Perren MJ, Connor HE, Ward P, Beattie DT. The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system. Regul Pept 1997 Jan 15;68(1):23-29.
222. Huttunen M, Harvima IT, Ackermann L, Harvima RJ, Naukkarinen A, Horsmanheimo M. Neuropeptide- and capsaicin-induced histamine release in skin monitored with the microdialysis technique. Acta Derm Venereol 1996 May;76(3):205-209.
223. Fjellner B, Hagermark O. Studies on pruritogenic and histaminereleasing effects of some putative peptide neurotransmitters. Acta Derm Venereol 1981;61(3):245-250.
224. Rukwied R, Heyer G. Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. Exp Dermatol 1999 Feb;8(1):39-45.
225. Anand P, Bloom SR, McGregor GP. Topical capsaicin pretreatment inhibits axon reflex vasodilatation caused by somatostatin and vasoactive intestinal polypeptide in human skin. Br J Pharmacol 1983 Apr;78(4):665-669.
226. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998 Feb;79(2):964-982.